Please assess the completion status of the following clinical trial:

Trial Title: PF-06372865 in Subjects With Photosensitive Epilepsy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* A diagnosis and history of photoparoxysmal response on electroencephalogram (EEG) with or without a diagnosis of epilepsy for which subjects are taking up to 0 - 2 concomitant antiepileptic drugs.~* Subjects currently taking antiepileptic drug(s) to be on a stable dose for 4 weeks prior to Screening Visit.~* A minimum average standardized photosensitive range (SPR) across all screening timepoints of 4 in the most sensitive eye condition and a non-zero average in at least one other eye condition.~Exclusion Criteria:~* Subjects with a history of status epilepticus.~* Subjects who have experienced a generalized tonic-clonic convulsion in the past 6 months, at the time of the initial screening visit.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- PF-06372865 dose level 1 (Type: EXPERIMENTAL): 17.5 milligram (mg) single dose
- PF-06372865 dose level 2 (Type: EXPERIMENTAL): 52.5 mg single dose
- Placebo (Type: PLACEBO_COMPARATOR): Single dose
- Lorazepam (Type: ACTIVE_COMPARATOR): 2mg single dose

Based on this trial design, predict the completion outcome and termination type (if applicable).